Skip to main content
Premium Trial:

Request an Annual Quote

MGI Tech, Predica Diagnostics Partner to Develop RNA-Based Cancer Screening Tests

NEW YORK – MGI Tech said Thursday that it has partnered with Dutch oncology diagnostics firm Predica Diagnostics to develop targeted RNA sequencing assays on MGI’s next-generation sequencing platforms.

Financial details of the deal were not disclosed.

As part of the collaboration, MGI and Predica, a spinoff from Radboud University Medical Center, plan to develop sequencing tests for early cancer detection and precision medicine that are "rapid, accurate, and affordable." Specifically, they will combine Predica’s proprietary circular probe-based RNA sequencing (ciRNA-seq) cervical cancer screening test, CervicaDx, with MGI’s DNBSeq platforms.

"By combining our affordable and high-performance sequencing technology with Predica's expert diagnostic kits, we are poised to make a significant impact in the field of personalized medicine," Yong Hou, MGI's general manager of Europe and Africa, said in a statement.